Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes.
Tian J, Song YP, Zhang GC, Wang SF, Chu XX, Chai Y, Wang CL, He AL, Zhang F, Shen XL, Zhang WH, Yang LH, Nie DN, Wang DM, Zhu HL, Gao D, Lou SF, Zhou ZP, Su GH, Li Y, Lin JY, Shi QZ, Ouyang GF, Jing HM, Chen SJ, Li J, Mi JQ.
Tian J, et al. Among authors: zhang gc.
J Cancer Res Clin Oncol. 2024 Apr 11;150(4):189. doi: 10.1007/s00432-024-05700-x.
J Cancer Res Clin Oncol. 2024.
PMID: 38605258
Free PMC article.
Clinical Trial.